Glucocorticoid-induced osteoporosis

Wanda Foltyn; Beata Kos-Kudła; Bogdan Marek; Dariusz Kajdaniuk; Joanna Głogowska-Szeląg; Lucyna Siemińska; Janusz Strzelczyk; Małgorzata Borowska

Vol 58, No 2 (2007)

REVIEWS — Postgraduate Education

Published online: 2007-03-13

Submitted: 2013-02-15

View PDF (polish)

Download PDF file

Get Citation

Glucocorticoid-induced osteoporosis

Wanda Foltyn, Beata Kos-Kudła, Bogdan Marek, Dariusz Kajdaniuk, Joanna Głogowska-Szeląg, Lucyna Siemińska, Janusz Strzelczyk, Małgorzata Borowska

Endokrynologia Polska 2007;58(2):170-176.

Vol 58, No 2 (2007)

REVIEWS — Postgraduate Education

Published online: 2007-03-13

Submitted: 2013-02-15

Abstract

Prolonged glucocorticoids administration is the most common cause of secondary osteoporosis. It is estimated that 30% to 50% of chronic glucocorticoids users experience vertebral or hip fractures. The highest bone loss (up to 30% in some studies) is observed in the first six months of treatment. Only a minority of patients who take chronic glucocorticoids receive optimal osteoporosis diagnosis, prevention, and/or treatment. The aim of this paper is to present the pathophysiology of glucocorticoid-induced osteoporosis, as well as some guidelines on diagnostic, preventive and therapeutic strategies for this disorder in an effort to promote the greater awareness of it.